Shanta S Bist

US Patent:

20080132546, Jun 5, 2008

Filed:

Dec 4, 2007

Appl. No.:

11/950105

Inventors:

Gregory Steven Basarab - Waltham MA, US
Shanta Bist - Waltham MA, US
John Irvin Manchester - Waltham MA, US
Brian Sherer - Waltham MA, US

Assignee:

AstraZeneca AB - Sodertalje

International Classification:

A61K 31/5377
C07D 213/06
C07D 417/04
C07D 401/04
A61K 31/44
A61P 43/00
C07D 403/04
A61K 31/506
C07D 413/14

US Classification:

514338, 546309, 5462704, 5462681, 514352, 514342, 514336, 544331, 514275, 544128, 5142352

Abstract:

Compounds of formula (I) and their pharmaceutically acceptable salts are described. Processes for their preparation, pharmaceutical compositions containing them, their use as medicaments and their use in the treatment of bacterial infections are also described.

US Patent:

20090253671, Oct 8, 2009

Filed:

Mar 2, 2006

Appl. No.:

11/817732

Inventors:

Shanta Bist - Nashua NH, US
Sheila Irene Hauck - Waltham MA, US
Kenneth Gregory Hull - Marlborough MA, US

Assignee:

ASTRAZENECA AB - Sodertalje

International Classification:

A61K 31/397
C07D 417/12
C07D 403/12
A61K 31/506
A61K 31/427
A61K 31/4025
A61P 31/00

US Classification:

5142102, 548146, 544242, 548400, 548537

Abstract:

Compounds of formula (I) and their pharmaceutically acceptable salts are described. Processes for their preparation, pharmaceutical compositions containing them, their use as medicaments and their use in the treatment of bacterial infections are also described.

US Patent:

20120101100, Apr 26, 2012

Filed:

Feb 25, 2009

Appl. No.:

12/392730

Inventors:

Shanta Bist - Waltham MA, US
Brian Dangel - Waltham MA, US
Brian Sherer - Waltham MA, US

International Classification:

A61K 31/5377
A61K 31/444
A61P 31/04
A61K 31/5025
C07D 413/14
C07D 401/14
C07D 487/04

US Classification:

5142368, 546256, 514333, 544236, 514248, 544131

Abstract:

Compounds of formula (I) and their pharmaceutically acceptable salts are described. Processes for their preparation, pharmaceutical compositions containing them, their use as medicaments and their use in the treatment of bacterial infections are also described.

US Patent:

20160175290, Jun 23, 2016

Filed:

Feb 29, 2016

Appl. No.:

15/056090

Inventors:

- London, GB
Shanta Bist - Nashua NH, US
Neil Bifulco - Sudbury MA, US
Liang Zhao - Lexington MA, US
Ye Wu - Waltham MA, US
Hoan Huynh - Waltham MA, US
Hui Xiong - Chesterbrook PA, US
Janelle Comita-Prevoir - Northborough MA, US
Daemian Dussault - Lowell MA, US
Bolin Geng - Andover MA, US
Brendan Chen - Sudbury MA, US
Thomas Francois Durand-Reville - Belmont MA, US
Satenig Guler - Waltham MA, US

International Classification:

A61K 31/439
A61K 31/546
A61K 31/407
A61K 31/4545
A61K 31/43
A61K 31/427
A61K 31/675
A61K 31/444
C07D 471/08
A61K 31/496

Abstract:

The present invention is directed to compounds which are beta-lacatamase inhibitors. The compounds and their pharmaceutically acceptable salts, are useful in combination with beta-lactam antibiotics, or alone, for the treatment of bacterial infections, including infections caused by drug resistant organisms, including multi-drug resistant organisms. The present invention includes compounds according to formula (Ia):or a pharmaceutically acceptable salt thereof, wherein the values of R, R, Rand Rare described herein.

US Patent:

20150073011, Mar 12, 2015

Filed:

Apr 2, 2013

Appl. No.:

14/389854

Inventors:

- Sodertalje, SE
Shanta Bist - Waltham MA, US
Neil Bifulco - Waltham MA, US
Liang Zhao - Waltham MA, US
Ye Wu - Waltham MA, US
Hoan Huynh - Waltham MA, US
Hui Xiong - Waltham MA, US
Janelle Comita-Prevoir - Waltham MA, US
Daemian Dussault - Waltham MA, US
Bolin Geng - Waltham MA, US
Brendan Chen - Waltham MA, US
Thomas Durand-Reville - Waltham MA, US
Satenig Guler - Waltham MA, US

Assignee:

ASTRAZENECA AB - Sodertalje

International Classification:

C07D 471/08

US Classification:

514300, 546121

Abstract:

The present invention is directed to compounds which are beta-lacatamase inhibitors. The compounds and their pharmaceutically acceptable salts, are useful in combination with beta-lactam antibiotics, or alone, for the treatment of bacterial infections, including infections caused by drug resistant organisms, including multi-drug resistant organisms. The present invention includes compounds according to formula (Ia):or a pharmaceutically acceptable salt thereof, wherein the values of R, R, Rand Rare described herein.